Efavirenz, lamivudine, and stavudine is a combination antiretroviral medication containing the active constituents efavirenz, lamivudine, and stavudine. It is used to treat HIV–1 infection. HIV–1 is a Human immunodeficiency virus that attacks and destroys the cells involved in the immune system. It decreases the body’s ability to fight against infections decreases and leads to death if untreated properly. CD4 cells, or T-helper cells, are a crucial immune system component. HIV attacks and destroys CD4 cells, which weakens the immune system. This medication can help increase CD4 cell counts, indicating immune system recovery and improved defense against infections. Efavirenz received initial FDA approval on September 17, 1998. Lamivudine obtained initial FDA approval on November 17, 1995. Stavudine received initial FDA approval on June 24, 1994.

It is used in the treatment of HIV infection.

It is an orally available prescription drug. Healthcare providers decide the dose and duration of Efavirenz, lamivudine, and stavudine based on the disease condition and other factors such as body weight and age. Take the tablet at the same time, with or without food. Do not break, chew, crush, or break the tablet. Swallow the whole tablet with a glass of water.

Side effects associated with the combined use of efavirenz, lamivudine, and stavudine may include central nervous system effects such as dizziness and mood changes, gastrointestinal symptoms such as nausea and diarrhea, potential liver toxicity, skin rash, elevated blood lipid levels, and changes in body fat distribution.

Using efavirenz, lamivudine, and stavudine carries important warnings that should be considered. These include the risk of central nervous system effects such as dizziness and mood changes, potential hepatotoxicity (liver toxicity), and hypersensitivity reactions. The other possible effects can be the possibility of lipodystrophy (distribution of body fat) and metabolic effects, renal impairment with stavudine, immune reconstitution inflammatory syndrome (worsening of condition after antiviral therapy), and treatment failure.

Precautions for the use of efavirenz, lamivudine, and stavudine include closely monitoring for central nervous system effects and liver function, promptly reporting hypersensitivity reactions, monitoring renal function in stavudine users, carefully evaluating risks in pregnancy, ensuring adherence to prevent treatment failure and drug resistance, monitoring for changes in body fat distribution, considering pediatric dosage adjustments, being aware of immune reconstitution inflammatory syndrome, and maintaining open communication with healthcare providers.

It is essential to get medical advice and adhere to a recommended treatment plan if you have HIV or are at risk of infection. Antiretroviral medication can greatly enhance your health results, such as combining Efavirenz, lamivudine, and stavudine. However, it is critical to remember that medication compliance is crucial. Place a high priority on routinely checking renal, liver, and general health. Pregnant or nursing women should speak with a doctor before beginning the treatment.

Additionally, using clean needles, engaging in safe sexual behavior, and adopting preventative steps can all greatly lower the chance of HIV transmission. Don't forget to consult healthcare professionals for personalized advice and direction for your needs and circumstances. Do not share needles or other items that may have blood or body fluids on them. Dose adjustment may require in pediatric and old age.

1. KD Tripathi, Essentials of Medical Pharmacology, Antiviral drugs, 7th edition, 2013, 806 - 811
2. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Antiretroviral agents and treatment of HIV infection, 12th edition, 2011, 1632-1634
3. Strides Arcolab Limited, US Food and Drug Administration, [ Accessed on 23rd May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/pepfar/022097PI.pdf
4. Pharmadox Healthcare Ltd, Electronic medicines compendium (EMC), [Revised on March 2019], [ Accessed on 23rd May 2023],https://www.medicines.org.uk/emc/files/pil.2066.pdf

The drug information on this page is different from medical advice. It is meant for educational purposes only. For further details, consult your doctor about your medical condition to know if you can receive this treatment.